Recent Blog Articles
Testosterone-blocking drugs boost heart disease risk when given in combination
Parenting isn't easy: Two important skills can help
Does sleeping with an eye mask improve learning and alertness?
Do tattoos cause lymphoma?
Hot weather hikes: Staying safe when temperatures spike
Cannabis drinks: How do they compare to alcohol?
What is Lewy body dementia?
Dog bites: How to prevent or treat them
Ever read your medical record? Here's why you should
Shining light on night blindness
Adam S. Cheifetz, MD
Contributor
Dr. Adam Cheifetz is director of the center for inflammatory bowel disease and medical director of infusion services at Beth Israel Deaconess Medical Center, and professor of medicine at Harvard Medical School. He is a well-recognized leader in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. He is involved in multiple research projects relating to IBD, and has published over 200 articles and chapters on the subject.
His research currently focuses on therapeutic drug monitoring and optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care.
Recent Blog Articles
Testosterone-blocking drugs boost heart disease risk when given in combination
Parenting isn't easy: Two important skills can help
Does sleeping with an eye mask improve learning and alertness?
Do tattoos cause lymphoma?
Hot weather hikes: Staying safe when temperatures spike
Cannabis drinks: How do they compare to alcohol?
What is Lewy body dementia?
Dog bites: How to prevent or treat them
Ever read your medical record? Here's why you should
Shining light on night blindness